Stivarga for GIST tumors
GIST(Gastrointenstinal Stromal Tumor) is the most common form of sarcoma in the gastrointestinal tract. There are thought to be 4,000-5,000 new cases of GIST diagnosed each year in the USA, about 1,500 of them metastatic. Two treatments for GIST has been recently FDA approved. Recently, FDA also approved regorefanib, Stivarga, for colon cancer, based on the CORRECT trial. The application for approval is for GIST is now pending before the FDA.
Read more